Hutchings Catherine J
Independent Consultant, UK.
Antib Ther. 2020 Dec 9;3(4):257-264. doi: 10.1093/abt/tbaa023. eCollection 2020 Dec.
Antibodies are now well established as therapeutics with many additional advantages over small molecules and peptides relative to their selectivity, bioavailability, half-life and effector function. Major classes of membrane-associated protein targets include G protein-coupled receptors (GPCRs) and ion channels that are linked to a wide range of disease indications across all therapeutic areas. This mini-review summarizes the antibody target landscape for both GPCRs and ion channels as well as current progress in the respective research and development pipelines with some example case studies highlighted from clinical studies, including those being evaluated for the treatment of symptoms in COVID-19 infection.
抗体作为治疗药物已得到充分确立,相对于小分子和肽,它们在选择性、生物利用度、半衰期和效应器功能方面具有许多额外优势。主要的膜相关蛋白靶点类别包括G蛋白偶联受体(GPCRs)和离子通道,它们与所有治疗领域的广泛疾病适应症相关。本综述总结了GPCRs和离子通道的抗体靶点情况,以及各自研发管线的当前进展,并重点介绍了一些临床研究中的实例,包括那些正在评估用于治疗COVID-19感染症状的研究。